Cretostimogene Grenadenorepvec
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Muscle Invasive Bladder Cancer
Conditions
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Trial Timeline
Oct 27, 2020 → Dec 24, 2031
NCT ID
NCT04452591About Cretostimogene Grenadenorepvec
Cretostimogene Grenadenorepvec is a phase 3 stage product being developed by CG Oncology for Non Muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04452591. Target conditions include Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06443944 | Pre-clinical | Active |
| NCT06567743 | Phase 2 | Recruiting |
| NCT06111235 | Phase 3 | Active |
| NCT04452591 | Phase 3 | Active |
Competing Products
20 competing products in Non Muscle Invasive Bladder Cancer